Results 61 to 70 of about 10,060 (149)

Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome

ACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors
Daniel Montes, Hannah E. Langenfeld, Andrew C. Hanson, Cynthia S. Crowson, Mrinal M. Patnaik, Ronald S. Go, Kambiz Kalantari, Yael Kusne, Terra Lasho, Abhishek A. Mangaonkar, Horatiu Olteanu, Kaaren K. Reichard, Megan M. Sullivan, David S. Viswanatha, Kenneth J. Warrington, Matthew J. Koster   +15 more
wiley   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, Volume 78, Issue 10, Page 2171-2178, October 2026.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Is Canakinumab Safe During Pregnancy? New Insights from Three Cases in Slovakia

Biologics
Background and Objectives: Canakinumab, a human recombinant monoclonal antibody against interleukin-1ß (IL-1ß), is indicated for the treatment of selected autoinflammatory periodic fever syndromes and rheumatic diseases.
Branislav Slenker, Katarina Hrubiskova, Lenka Kapustova, Anna Bobcakova, Juraj Ondris, Milos Jesenak   +5 more
doaj   +1 more source

Molecular and Cellular Underpinnings of Primary Hypertension: An Integrative Mechanistic Framework

Journal of Cellular Physiology, Volume 241, Issue 10, October 2026.
ABSTRACT Hypertension is a highly prevalent clinical condition and a major contributor to global cardiovascular morbidity and mortality. Despite extensive research, its complex and multifaceted pathogenesis is yet to be fully elucidated. This paper explores the updated understanding of primary hypertension as a systemic disorder rather than an isolated
Dima Nasrallah, Alaa Abdelhamid, Omar Tluli, Yaman Al‐Haneedi, Mera Abu Hussien, Ali H. Eid   +5 more
wiley   +1 more source

Neutrophil Extracellular Traps in Atherosclerosis and Cardiovascular Disease

MedComm, Volume 7, Issue 10, October 2026.
NETs as integrated effectors in the atherosclerotic cardiovascular disease continuum. Activated neutrophils release NETs that promote endothelial injury, thrombo‐inflammation, and plaque destabilization throughout atherosclerotic disease progression. Created with BioRender.com.
Ji Zhang, Fangjiaqi Wei, Mengdi Qu, Yuwen Shao, Tingye Xu, Darko Stojkov, Hans‐Uwe Simon, Ben Huang, Changhong Miao, Hao Zhang   +9 more
wiley   +1 more source

Clinical management of clonal hematopoiesis

Cancer, Volume 132, Issue 18, 15 September 2026.
ABSTRACT Clonal hematopoiesis, particularly clonal hematopoiesis of indeterminate potential and clonal cytopenia of undetermined significance, is an age‐related premalignant condition characterized by the expansion of hematopoietic clones carrying somatic mutations.
Kelly S. Chien, Guillermo Garcia‐Manero   +1 more
wiley   +1 more source

Experience of the Successful Treatment With Canakinumab of a Patient With Systemic Juvenile Idiopathic Arthritis

Вопросы современной педиатрии, 2017
The article presents the follow-up of a patient with severe systemic juvenile idiopathic arthritis (JIA) resistant to glucocorticosteroids, to the first genetically engineered biologic drug (GEBD) tocilizumab, a monoclonal antibody to the interleukin (IL)
Ekaterina I. Alexeeva, Olga L. Lomakina, Tatiana M. Bzarova   +2 more
doaj   +1 more source

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)

Pharmaceuticals
Background: Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential.
Weidong Zhang, Yunzhou Chen, Zeyu Yao, Mengling Ouyang, Minghui Sun, Shupeng Zou   +5 more
doaj   +1 more source

Acute Pustular Facial Eruption in a 5‐Year‐Old Boy

Pediatric Dermatology, EarlyView.
Naia Oillarburu, Magalie Coco‐Viloin, Emilie Tournier, Juliette Mazereeuw‐Hautier, Maella Severino‐Freire   +4 more
wiley   +1 more source

The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells.

PLoS ONE
Muscle inflammation is one of the hallmarks of Duchenne muscular dystrophy (DMD). Dystrophin-deficient skeletal muscle cells produce higher levels of pro-inflammatory cytokines such as interleukin 1β (IL-1β) in response to toll-like receptor stimulation ...
Anna Cordeiro-Santanach, Fiorella Morales, Maria Del Carmen Parquet, Kitipong Uaesoontrachoon, Joyce Rowsell, Jordan Warford, Wilson Wu, Pia Elustondo, Eric P Hoffman, Kanneboyina Nagaraju   +9 more
doaj   +1 more source